Initiator Pharma A/S, a clinical-stage biotech company today announced that the screening of patients for the Phase 2a clinical trial with IP2018 is still ongoing and the first dosing of patients is expected shortly.
Initiator Pharma has been made aware of that, in the recently published teaser for the ongoing exercise period for the warrants of series TO 2, there is information on the Phase 2a clinical trial with IP2018 stating both that the dosing of the first patient is expected shortly - and that the first patient already has been dosed. The correct information is, as previously communicated, that the screening of patients is still ongoing and the first dosing of patients is expected shortly.
For more information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone number: +45 6126 0035
The information was provided by the contact person above, to be published on December 8, 2020, at 14:50 (CET) .
About Initiator Pharma
Initiator Pharma is a clinical-stage biotechnology company based in Aarhus, Denmark. The company’s main clinical Phase assets are IPED2015, intended for patients with erectile dysfunction, and IP2018, for the treatment of psychogenic erectile dysfunction. The treatments both represent First in Class treatments for psychogenic and organic ED, respectively, and are expected to improve the quality of life for a growing number of patients who are not responding to or cannot be treated with existing drugs on the market. Read more on www.initiatorpharma.com.